S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Is Gold Really Boring? (Ad)
Palo Alto Networks aims at cyber security leadership
3 Reasons the Capital One-Discover merger is a big deal
Is Gold Really Boring? (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Housing data weakens, but Toll Brothers stock is still a buy
Teladoc Health gaps down to support level after weak guidance
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Is Gold Really Boring? (Ad)
Palo Alto Networks aims at cyber security leadership
3 Reasons the Capital One-Discover merger is a big deal
Is Gold Really Boring? (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Housing data weakens, but Toll Brothers stock is still a buy
Teladoc Health gaps down to support level after weak guidance
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Is Gold Really Boring? (Ad)
Palo Alto Networks aims at cyber security leadership
3 Reasons the Capital One-Discover merger is a big deal
Is Gold Really Boring? (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Housing data weakens, but Toll Brothers stock is still a buy
Teladoc Health gaps down to support level after weak guidance
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Is Gold Really Boring? (Ad)
Palo Alto Networks aims at cyber security leadership
3 Reasons the Capital One-Discover merger is a big deal
Is Gold Really Boring? (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Housing data weakens, but Toll Brothers stock is still a buy
Teladoc Health gaps down to support level after weak guidance
NASDAQ:GDRX

GoodRx (GDRX) Stock Price, News & Analysis

$6.54
+0.11 (+1.71%)
(As of 02/21/2024 ET)
Today's Range
$6.27
$6.58
50-Day Range
$5.37
$6.73
52-Week Range
$4.14
$9.37
Volume
1.54 million shs
Average Volume
888,618 shs
Market Capitalization
$2.66 billion
P/E Ratio
163.54
Dividend Yield
N/A
Price Target
$8.00

GoodRx MarketRank™ Stock Analysis

Analyst Rating
Hold
2.21 Rating Score
Upside/​Downside
22.3% Upside
$8.00 Price Target
Short Interest
Bearish
13.05% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.67mentions of GoodRx in the last 14 days
Based on 8 Articles This Week
Insider Trading
Acquiring Shares
$149,658 Bought Last Quarter
Proj. Earnings Growth
44.44%
From $0.09 to $0.13 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.21 out of 5 stars

Medical Sector

535th out of 932 stocks

Data Processing & Preparation Industry

32nd out of 56 stocks


GDRX stock logo

About GoodRx Stock (NASDAQ:GDRX)

GoodRx Holdings, Inc., through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States. It also offers other healthcare products and services, including subscriptions, pharma manufacturer solutions, and telehealth services. It serves pharmacy benefit managers that manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. GoodRx Holdings, Inc. was incorporated in 2015 and is headquartered in Santa Monica, California.

GDRX Stock Price History

GDRX Stock News Headlines

Gene therapy: Why does it cost millions for a single treatment?
Gene therapy treatments have been making major headlines as advances in gene editing have gone mainstream thanks to the advent of CRISPR/Cas-9 technology. The shot heard around the world in the medical sector occurred on December 8, 2023, when the U.S. FDA approved Casgevy, the first FDA-approved gene-editing treatment for sickle cell disease (SCD) from Vertex Pharmaceuticals Inc. NASDAQ: VRTX and co-developed by CRISPR Therapeutics AG NASDAQ: CRSP.
Gene therapy: Why does it cost millions for a single treatment? (GDRX)
Gene therapy treatments have been making major headlines as advances in gene editing have gone mainstream thanks to the advent of CRISPR/Cas-9 technology.
Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
GoodRx (GDRX) Set to Announce Quarterly Earnings on Thursday
GoodRx to Participate in Upcoming Investor Conferences
GoodRx to Participate in Upcoming Investor Conferences
GDRX Mar 2024 7.500 put
Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
Goodrx Holdings Inc (GDRX)
See More Headlines
Receive GDRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GoodRx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2023
Today
2/22/2024
Next Earnings (Confirmed)
2/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Data processing & preparation
Sub-Industry
N/A
Current Symbol
NASDAQ:GDRX
Fax
N/A
Employees
952
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.00
High Stock Price Target
$12.00
Low Stock Price Target
$4.50
Potential Upside/Downside
+22.3%
Consensus Rating
Hold
Rating Score (0-4)
2.21
Research Coverage
14 Analysts

Profitability

Net Income
$-32,830,000.00
Pretax Margin
-4.84%

Debt

Sales & Book Value

Annual Sales
$766.55 million
Cash Flow
$0.23 per share
Book Value
$2.05 per share

Miscellaneous

Free Float
400,568,000
Market Cap
$2.66 billion
Optionable
Optionable
Beta
1.33
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report














GDRX Stock Analysis - Frequently Asked Questions

Should I buy or sell GoodRx stock right now?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GoodRx in the last year. There are currently 1 sell rating, 9 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" GDRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GDRX, but not buy additional shares or sell existing shares.
View GDRX analyst ratings
or view top-rated stocks.

What is GoodRx's stock price target for 2024?

14 Wall Street analysts have issued 12 month price targets for GoodRx's stock. Their GDRX share price targets range from $4.50 to $12.00. On average, they anticipate the company's share price to reach $8.00 in the next twelve months. This suggests a possible upside of 22.3% from the stock's current price.
View analysts price targets for GDRX
or view top-rated stocks among Wall Street analysts.

How have GDRX shares performed in 2024?

GoodRx's stock was trading at $6.70 at the beginning of 2024. Since then, GDRX shares have decreased by 2.4% and is now trading at $6.54.
View the best growth stocks for 2024 here
.

When is GoodRx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 29th 2024.
View our GDRX earnings forecast
.

How can I listen to GoodRx's earnings call?

GoodRx will be holding an earnings conference call on Thursday, February 29th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were GoodRx's earnings last quarter?

GoodRx Holdings, Inc. (NASDAQ:GDRX) released its quarterly earnings data on Thursday, November, 9th. The company reported $0.06 EPS for the quarter, meeting analysts' consensus estimates of $0.06. The company earned $180 million during the quarter, compared to analysts' expectations of $188.52 million. GoodRx had a net margin of 2.04% and a trailing twelve-month return on equity of 2.25%. The business's quarterly revenue was down 3.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.07 EPS.

What ETFs hold GoodRx's stock?
What guidance has GoodRx issued on next quarter's earnings?

GoodRx updated its FY 2023 earnings guidance on Tuesday, January, 30th. The company provided EPS guidance of for the period. The company issued revenue guidance of $759.0 million-$761.0 million, compared to the consensus revenue estimate of $744.3 million.

What other stocks do shareholders of GoodRx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GoodRx investors own include Gilead Sciences (GILD), NVIDIA (NVDA), AbbVie (ABBV), Bristol-Myers Squibb (BMY), DraftKings (DKNG), GW Pharmaceuticals (GWPH), Rocket Companies (RKT), AT&T (T), Advanced Micro Devices (AMD) and Alteryx (AYX).

When did GoodRx IPO?

(GDRX) raised $900 million in an initial public offering on Wednesday, September 23rd 2020. The company issued 34,600,000 shares at $24.00-$28.00 per share. Morgan Stanley, Goldman Sachs, J.P. Morgan and Barclays served as the underwriters for the IPO and BofA Securities, Citigroup, Credit Suisse, RBC Capital Markets, UBS Investment Bank, Cowen, Deutsche Bank Securities, Evercore ISI, Citizens Capital Markets, KKR, LionTree, Raymond James, SVB Leerink, Academy Securities, Loop Capital Markets, R. Seelaus and Ramirez were co-managers.

Who are GoodRx's major shareholders?

GoodRx's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (2.06%), Rubric Capital Management LP (1.45%), Dimensional Fund Advisors LP (0.44%), Rip Road Capital Partners LP (0.43%), Assenagon Asset Management S.A. (0.33%) and Invenomic Capital Management LP (0.12%). Insiders that own company stock include Abdiel Capital Management, Llc, Agnes Rey-Giraud, Andrew Slutsky, Babak Azad, Bansi Nagji, Douglas Joseph Hirsch, Idea Men, Llc, Karsten Voermann, Lake Group LLC Silver, Scott Wagner and Trevor Bezdek.
View institutional ownership trends
.

How do I buy shares of GoodRx?

Shares of GDRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GDRX) was last updated on 2/22/2024 by MarketBeat.com Staff